PURIFICATION TO HOMOGENEITY AND PARTIAL CHARACTERIZATION OF CYTOTOXIC LYMPHOCYTE MATURATION FACTOR FROM HUMAN B-LYMPHOBLASTOID CELLS

被引:687
作者
STERN, AS
PODLASKI, FJ
HULMES, JD
PAN, YCE
QUINN, PM
WOLITZKY, AG
FAMILLETTI, PC
STREMLO, DL
TRUITT, T
CHIZZONITE, R
GATELY, MK
机构
[1] HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT IMMUNOPHARMACOL,NUTLEY,NJ 07110
[2] HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT BIOPROC DEV,NUTLEY,NJ 07110
[3] HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT MOLEC GENET,NUTLEY,NJ 07110
关键词
Interleukin; 2; Lymphokine-activated killer cells; Natural killer cell; T-cell growth factor; Tumor necrosis factor;
D O I
10.1073/pnas.87.17.6808
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A cytokine that can synergize with interleukin 2 to activate cytotoxic lymphocytes was purified to homogeneity. The protein, provisionally called cytotoxic lymphocyte maturation factor (CLMF), was isolated from a human B-lymphoblastoid cell line that was induced to secrete lymphokines by culture with phorbol ester and calcium ionophore. The purification method, utilizing classical and high-performance liquid chromatographic techniques, yielded protein with a specific activity of 8.5 × 107 units/mg in a T-cell growth factor assay. Analysis of the purified protein by sodium dodecyl sulfate/polyacrylamide gel electrophoresis demonstrated that CLMF is a 75-kDa heterodimer composed of disulfide-bonded 40-kDa and 35-kDa subunits. Determination of the N-terminal amino acid sequences of the two subunits revealed that both subunits are not related to any previously identified cytokine. Purified CLMF stimulated the proliferation of human phytohemagglutinin-activated lymphoblasts by itself and exerted additive effects when used in combination with suboptimal amounts of interleukin 2. Furthermore, the purified protein was shown to synergize with low concentrations of interleukin 2 in causing the induction of lymphokine-activated killer cells.
引用
收藏
页码:6808 / 6812
页数:5
相关论文
共 28 条
  • [1] BRUNDA MJ, 1985, MECHANISMS CYTOTOXIC, P397
  • [2] CAMERON RB, 1988, CANCER RES, V48, P5810
  • [3] THE TREATMENT OF INDUCED IMMUNE-DEFICIENCY WITH INTERLEUKIN-2
    CONLON, PJ
    WASHKEWICZ, TL
    MOCHIZUKI, DY
    URDAL, DL
    GILLIS, S
    HENNEY, CS
    [J]. IMMUNOLOGY LETTERS, 1985, 10 (06) : 307 - 314
  • [4] CRUMP WL, 1989, CANCER RES, V49, P149
  • [5] GATELY MK, 1986, J IMMUNOL, V136, P1274
  • [6] GATELY MK, 1982, J NATL CANCER I, V69, P1245
  • [7] GILLIS S, 1979, J IMMUNOL, V123, P1624
  • [8] HEWICK RM, 1981, J BIOL CHEM, V256, P7990
  • [9] Hussa R O, 1980, Endocr Rev, V1, P268
  • [10] IIGO M, 1988, CANCER RES, V48, P260